| Title | Clinical and Experimental Metastasis |
| Abbreviation | Clin. Exp. Metastasis |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Medicine (miscellaneous) (Q1); Cancer Research (Q2); Oncology (Q2) |
| h-index | 107 |
| Overall Rank/Ranking | 3457 |
| SCImago Journal Rank (SJR) | 1.125 |
| Impact Score | 3.74 |
| Publisher | Springer Netherlands |
| Country | Netherlands |
| ISSN | 02620898, 15737276 |
| Best Quartile | Q1 |
| Coverage History | 1983-2022 |
Clinical & Experimental Metastasis is an international, multidisciplinary journal devoted to the rapid publication of fundamental advances in basic and applied metastasis research.
The coverage encompasses all aspects of metastasis research, whether laboratory-based, experimental or clinical and therapeutic. It includes such areas as molecular biology, pharmacology, tumour biology, and clinical cancer treatment (with all its subdivisions of surgery, chemotherapy and radio-therapy as well as pathology and epidemiology) insofar as these disciplines are concerned with the journal core subject of metastasis formation, prevention and treatment.
Clinical & Experimental Metastasis is the official journal of the Metastasis Research Society.
Clinical and Experimental Metastasis is a journal covering the technologies/fields/categories related to Medicine (miscellaneous) (Q1); Cancer Research (Q2); Oncology (Q2). It is published by Springer Netherlands. The overall rank of Clinical and Experimental Metastasis is 3457. According to SCImago Journal Rank (SJR), this journal is ranked 1.125. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 107. The best quartile for this journal is Q1.
The ISSN of Clinical and Experimental Metastasis journal is 02620898, 15737276. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Clinical and Experimental Metastasis is cited by a total of 688 articles during the last 3 years (Preceding 2022).
The Impact IF 2022 of Clinical and Experimental Metastasis is 3.74, which is computed in 2023 as per its definition. Clinical and Experimental Metastasis IF is decreased by a factor of 0.3 and approximate percentage change is -7.43% when compared to preceding year 2021, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2022 of Clinical and Experimental Metastasis is 3.74. If the same downward trend persists, Impact IF may fall in 2023 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3.74 |
| 2021 | 4.04 |
| 2020 | 4.31 |
| 2019 | 2.76 |
| 2018 | 2.48 |
| 2017 | 3.57 |
| 2016 | 3.36 |
| 2015 | 3.15 |
| 2014 | 3.75 |
Clinical and Experimental Metastasis has an h-index of 107. It means 107 articles of this journal have more than 107 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Clinical and Experimental Metastasis is 02620898, 15737276. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Clinical and Experimental Metastasis is 3457. According to SCImago Journal Rank (SJR), this journal is ranked 1.125. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 1.125 |
| 2021 | 1.108 |
| 2020 | 1.269 |
| 2019 | 1.340 |
| 2018 | 1.229 |
| 2017 | 1.397 |
| 2016 | 1.299 |
| 2015 | 1.341 |
| 2014 | 1.947 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3457 |
| 2021 | 3480 |
| 2020 | 3005 |
| 2019 | 2714 |
| 2018 | 3199 |
| 2017 | 2605 |
| 2016 | 2961 |
| 2015 | 2865 |
| 2014 | 1472 |
Clinical and Experimental Metastasis is published by Springer Netherlands. It's publishing house is located in Netherlands. Coverage history of this journal is as following: 1983-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Clinical and Experimental Metastasis is Clin. Exp. Metastasis. This abbreviation ('Clin. Exp. Metastasis') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Medicine (miscellaneous) (Q1); Cancer Research (Q2); Oncology (Q2), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Clinical and Experimental Metastasis latest impact IF is 3.74. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 4.31 (2020) and 2.48 (2018), respectively, in the last 9 years. Moreover, its average IS is 3.46 in the previous 9 years.
The Clinical and Experimental Metastasis has an SJR (SCImago Journal Rank) of 1.125, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 1.947 in 2014 and the lowest being 1.108 in 2021. Furthermore, the average SJR of the Clinical and Experimental Metastasis over the previous 9-year period stands at 3.46.
The latest h-index of the Clinical and Experimental Metastasis is 107.
The Clinical and Experimental Metastasis is published by the Springer Netherlands, with its country of publication being the Netherlands.
The Clinical and Experimental Metastasis is currently ranked 3457 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 1472 in 2014 and its lowest position of 3480 in 2021.
The standard ISO4 abbreviation for the Clinical and Experimental Metastasis is Clin. Exp. Metastasis.
Clinical and Experimental Metastasis is classified as a journal that the Springer Netherlands publishes.
The Clinical and Experimental Metastasis encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Clinical and Experimental Metastasis is assigned the following International Standard Serial Numbers (ISSN): 02620898, 15737276.
The best quartile for the Clinical and Experimental Metastasis is Q1 (2022).
The Clinical and Experimental Metastasis coverage history can be summarized as follows: 1983-2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Indian Journal of Plastic Surgery | journal | 16018 | Thieme Medical Publishers Inc. | 37 | 0.65 |
| Air and Space Power Journal (discontinued) | journal | 28397 | AU Press | 9 | 0.20 |
| Journal, Indian Academy of Clinical Medicine | journal | 24608 | Indian Academy of Clinical Medicine | 16 | 0.06 |
| Transnational Corporations | journal | 6120 | UNCTAD United Nations Conference on Trade and Development | 27 | 1.92 |
| Howard Journal of Communications | journal | 9564 | Taylor and Francis Ltd. | 36 | 1.66 |
| Tekstilec | trade journal | 19217 | Faculty of Natural Sciences and Engineering, Tekstilec | 14 | 0.73 |
| Canadian Journal of Mathematics | journal | 3905 | Canadian Mathematical Society | 43 | 0.79 |
| Expert Review of Clinical Pharmacology | journal | 5241 | Taylor and Francis Ltd. | 53 | 4.10 |
| Poljoprivreda | journal | 20724 | Faculty of Agriculture in Osijek | 14 | 0.67 |
| Psycho-Oncologie | journal | 24009 | Springer Paris | 11 | 0.13 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3.74 |
| 2021 | 4.04 |
| 2020 | 4.31 |
| 2019 | 2.76 |
| 2018 | 2.48 |
| 2017 | 3.57 |
| 2016 | 3.36 |
| 2015 | 3.15 |
| 2014 | 3.75 |
